Saturday, 31 October 2026European Markets

ELLIPTIC LABORATOR Stock Rises By 28% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of ELLIPTIC LABORATOR (Oslo Børs Benchmark Index_GI: ELABS.OL) jumped by a staggering 28.12% in 10 sessions from kr12.66 to kr16.22 at 20:22 EST on Tuesday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 0.33% to kr1,205.68, after two successive sessions in a row of gains.

About ELLIPTIC LABORATOR

Elliptic Laboratories ASA, an artificial intelligence (AI) software company, provides AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive industries in Norway, China, Taiwan, South Korea, the United States, and Japan. The company offers AI Virtual human Presence Sensor, a presence-detection solution used to improve the security of data stored on laptops ; AI Virtual Proximity Sensor that enables exquisite full-screen devices; AI Virtual Connection Sensor that allows to pair and authenticate smart devices in the same room; AI Virtual Position Sensor that automatically detects the location of an external display; AI Virtual Gesture Sensor, a touch-free ultrasound gesture technology; AI Virtual Breathing sensor that enables to track person breathing; and AI Virtual heart Sensor that tracks a person's heart rate. Elliptic Laboratories ASA was incorporated in 2006 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ELLIPTIC LABORATOR has a trailing twelve months EPS of kr-0.36.

Volatility

ELLIPTIC LABORATOR's last week, last month's, and last quarter's current intraday variation average was 3.17%, 2.53%, and 3.66%.

ELLIPTIC LABORATOR's highest amplitude of average volatility was 4.98% (last week), 4.63% (last month), and 3.66% (last quarter).

Volume

Today's last reported volume for ELLIPTIC LABORATOR is 322885 which is 17.57% above its average volume of 227798.

More news about ELLIPTIC LABORATOR (ELABS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com